lyophilized powder raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-02-23. Anything still debated is marked as such rather than presented as settled.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (no linker) | ~3.37 kDa | Calculated from peptide sequence |
| Molecular weight (with linker) | ~3.65 kDa | Includes albumin-binding moiety |
| Appearance | White to off-white powder | Typically lyophilized |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Common synonyms | Modified GRF(1-29), DAC:GRF | Usage varies by source |
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
As for SDF-1α, the release of lysine decreases its ability to function, so this enzyme acts as a regulator of activity; SDF-1α is normally important in hematopoietic stem cell trafficking. For plasminogen receptors, cleaving lysine prevents plasminogen's activation into plasmin. Lysine carboxypeptidase regulates enkephalin by reducing its affinity for kappa opioid receptors and consequently making it delta receptor specific. It is also suspected that epidermal growth factor (and possibly other growth factors), acts as a substrate since it is metabolized by the cleavage of C-terminal arginine. Other lesser studied substrates include fibrinopeptides which are involved in blood clotting. This enzyme is extremely important for proper functioning of the body. There are no records of a person who is completely missing lysine carboxypeptidase and lower than normal levels of the enzyme have been linked to disorders such as angioneurotic edema.
== History == TMA-2 was first described in the scientific literature by Viktor Bruckner in 1933. Subsequently, Alexander Shulgin discovered the hallucinogenic effects of TMA-2 in 1962 and published them in 1964. The drug was later described in further detail by Shulgin in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved).
The first company to use such method is Evonik company in 2000. The enzyme Lipase-CalB in its immobilized state is actually used in other pharmaceutical applications for the production of Odanacatib, and Sofosbuvir.
=== Electrochemical === Polarized liquid interfaces have been used to examine the thermodynamics and kinetics of the transfer of charged species from one phase to another. Two main methods exist. The first is ITIES, "interfaces between two immiscible electrolyte solutions". The second is droplet experiments. Here a reaction at a triple interface between a conductive solid, droplets of a redox active liquid phase and an electrolyte solution have been used to determine the energy required to transfer a charged species across the interface.
Sources: en.wikipedia.org
methane CH4 – one carbon and 4 hydrogen ethane C2H6 – two carbon and 6 hydrogen propane C3H8 – three carbon and 8 hydrogen butane C4H10 – four carbon and 10 hydrogen pentane C5H12 – five carbon and 12 hydrogen hexane C6H14 – six carbon and 14 hydrogen heptane C7H16 – seven carbons and 16 hydrogen octane C8H18 – eight carbons and 18 hydrogen The first four names were derived from methanol, ether, propionic acid and butyric acid. Alkanes with five or more carbon atoms are named by adding the suffix -ane to the appropriate numerical multiplier prefix with elision of any terminal vowel (-a or -o) from the basic numerical term. Hence, pentane, C5H12; hexane, C6H14; heptane, C7H16; octane, C8H18; etc. The numeral prefix is generally Greek; however, alkanes with a carbon atom count ending in nine, for example nonane, use the Latin prefix non-.
Spray lubricants may contain wax or PTFE. While these lubricants use tack additives to stay on the chain they can also attract dirt and sand from the road and over time produce a grinding paste that accelerates component wear. Oil drip feed systems continuously lubricate the chain and use light oil that does not stick to the chain. Research has shown that oil drip feed systems provide the greatest wear protection and greatest power saving.
=== Jabbar Trussell Braverman === Jabbar Trussell (Tyree Brown) is Jasmine and Crosby's son. He is five years old during the show's first season. He is recurring in season one, but is promoted to a regular role for all subsequent seasons.
=== Contraindications === Labia reduction surgery is relatively contraindicated for the woman who have active gynecological disease, such as an infection or a malignancy; the woman who is a tobacco smoker and is unwilling to quit, either temporarily or permanently, in order to optimize her wound-healing capability; and the woman who is unrealistic in her aesthetic goals. The latter should either be counselled or excluded from labioplastic surgery. Davison et al write that it should not be performed when the patient is menstruating to reduce potential hormonal effects and the increased risk of infection.
François Vandenesch; Timothy S Naimi; Mark Enright; et al. (2003). "Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence". Emerging Infectious Diseases. 9 (8): 978–984. doi:10.3201/eid0908.030089. PMC 3020611. PMID 12967497. Wikidata Q24598936. Cameron Burton; Emma Best; Matthew Broom; Helen Heffernan; Simon Briggs; Rachel Webb (2023). "Pediatric Invasive Meningococcal Disease, Auckland, New Zealand (Aotearoa), 2004–2020". Emerging Infectious Diseases. 29 (4): 686–695. doi:10.3201/eid2904.221397. PMID 36957984. Wikidata Q130355931. Deborah A Williamson; Hanna E. Sidjabat; Joshua T Freeman; et al. (2012). "Identification and molecular characterisation of New Delhi metallo-β-lactamase-1 (NDM-1)- and NDM-6-producing Enterobacteriaceae from New Zealand hospitals". International Journal of Antimicrobial Agents. 39 (6): 529–533. doi:10.1016/j.ijantimicag.2012.02.017. PMID 22526013. Wikidata Q48050341. Joshua T Freeman; Stephen J McBride; Helen Heffernan; Tracy Bathgate; Chris Pope; Roderick B Ellis-Pegler (2008). "Community-onset genitourinary tract infection due to CTX-M-15-Producing Escherichia coli among travelers to the Indian subcontinent in New Zealand". Clinical Infectious Diseases. 47 (5): 689–692. doi:10.1086/590941. PMID 18665816. Wikidata Q45138244. Rajan P Adhikari; Gregory M Cook; Iain Lamont; Selwyn Lang; Helen Heffernan; John M B Smith (2002). "Phenotypic and molecular characterization of community occurring, Western Samoan phage pattern methicillin-resistant Staphylococcus aureus".
Sources: en.wikipedia.org
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.
Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.
The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.